Accès gratuit
Numéro
Réanimation
Volume 25, Numéro 2, Mars 2016
Cardiovasculaire
Page(s) 145 - 154
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1167-y
Publié en ligne 1 février 2016
  • Logeart D, Isnard R, Resche-Rigon M, et al (2013) Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail 15:465–76 [CrossRef] [PubMed] [Google Scholar]
  • Tuppin P, Cuerq A, de Peretti C, et al (2013) First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis 106:570–85 [CrossRef] [PubMed] [Google Scholar]
  • Follath F, Yilmaz MB, Delgado JF, et al (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 37:619–26 [CrossRef] [PubMed] [Google Scholar]
  • Tarvasmaki T, Harjola VP, Nieminen MS, et al (2014) Acute heart failure with and without concomitant acute coronary syndromes: patient characteristics, management, and survival. J Card Fail 20:723–30 [CrossRef] [PubMed] [Google Scholar]
  • McMurray JJ, Adamopoulos S, Anker SD, et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–69 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Yilmaz MB, Levy P, et al (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17:544–58 [CrossRef] [PubMed] [Google Scholar]
  • Yancy CW, Jessup M, Bozkurt B, et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Tolppanen H, Mueller C, et al (2015) Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med [in press] [Google Scholar]
  • Harjola VP, Lassus J, Sionis A, et al (2015) Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 17:501–509 [CrossRef] [PubMed] [Google Scholar]
  • Logeart D, Isnard R, Resche-Rigon M, et al (2013) Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail 15:465–76 [CrossRef] [PubMed] [Google Scholar]
  • Thiele H, Zeymer U, Neumann FJ, et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. New Engl J Med 367:1287–96 [CrossRef] [PubMed] [Google Scholar]
  • Nieminen MS, Brutsaert D, Dickstein K, et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–36 [CrossRef] [PubMed] [Google Scholar]
  • Abraham WT, Adams KF, Fonarow GC, et al (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46:57–64 [CrossRef] [PubMed] [Google Scholar]
  • Nieminen MS, Akkila J, Hasenfuss G, et al (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903–12 [CrossRef] [PubMed] [Google Scholar]
  • Parissis JT, Paraskevaidis I, Bistola V, et al (2006) Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 98:1489–92 [CrossRef] [PubMed] [Google Scholar]
  • De Luca L, Proietti P, Celotto A, et al (2005) Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 150:563–8 [CrossRef] [PubMed] [Google Scholar]
  • Yilmaz MB, Yalta K, Yontar C, et al (2007) Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 21:431–5 [CrossRef] [PubMed] [Google Scholar]
  • Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A (2009) Levosimendan: from basic science to clinical practice. Heart Fail Rev 14:265–75 [CrossRef] [PubMed] [Google Scholar]
  • Follath F, Cleland JG, Just H, et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196–202 [CrossRef] [PubMed] [Google Scholar]
  • Cleland JG, Freemantle N, Coletta AP, Clark AL (2006) Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8:105–10 [CrossRef] [PubMed] [Google Scholar]
  • Moiseyev VS, Poder P, Andrejevs N, et al (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422–32 [CrossRef] [PubMed] [Google Scholar]
  • Mebazaa A, Nieminen MS, Packer M, et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297:1883–91 [CrossRef] [PubMed] [Google Scholar]
  • Arrigo M, Mebazaa A (2015) Understanding the differences among inotropes. Intensive Care Med 41:912–5 [CrossRef] [PubMed] [Google Scholar]
  • Cleland JG, Teerlink JR, Senior R, et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase II trial. Lancet 378:676–83 [CrossRef] [PubMed] [Google Scholar]
  • Teerlink JR, Clarke CP, Saikali KG, et al (2011) Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378:667–75 [CrossRef] [PubMed] [Google Scholar]
  • Levy PD, Laribi S, Mebazaa A (2014) Vasodilators in acute heart failure: review of the latest studies. Curr Emerg Hosp Med Rep 2:126–32 [CrossRef] [PubMed] [Google Scholar]
  • Teichman SL, Unemori E, Dschietzig T, et al (2009) Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 14:321–9 [CrossRef] [PubMed] [Google Scholar]
  • Teerlink JR, Metra M, Felker GM, et al (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373:1429–39 [CrossRef] [PubMed] [Google Scholar]
  • Teerlink JR, Cotter G, Davison BA, et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39 [CrossRef] [PubMed] [Google Scholar]
  • O'Connor CM, Starling RC, Hernandez AF, et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32–43 [CrossRef] [PubMed] [Google Scholar]
  • Anker SD, Ponikowski P, Mitrovic V, et al (2015) Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 36:715–23 [CrossRef] [PubMed] [Google Scholar]
  • Mitrovic V, Seferovic PM, Simeunovic D, et al (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27:2823–32 [CrossRef] [PubMed] [Google Scholar]
  • Nordlander M, Sjoquist PO, Ericsson H, Ryden L (2004) Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 22:227–50 [CrossRef] [PubMed] [Google Scholar]
  • Peacock WF, Chandra A, Char D, et al (2014) Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J 167:529–36 [CrossRef] [PubMed] [Google Scholar]
  • Gheorghiade M, Marti CN, Sabbah HN, et al (2013) Soluble guanylate-cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 18:123–34 [CrossRef] [PubMed] [Google Scholar]
  • Gheorghiade M, Greene SJ, Filippatos G, et al (2012) Cinaciguat, a soluble guanylate-cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14:1056–66 [CrossRef] [PubMed] [Google Scholar]
  • Erdmann E, Semigran MJ, Nieminen MS, et al (2013) Cinaciguat, a soluble guanylate-cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34:57–67 [CrossRef] [PubMed] [Google Scholar]
  • Bonderman D, Ghio S, Felix SB, et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–11 [CrossRef] [PubMed] [Google Scholar]
  • Gheorghiade M, Greene SJ, Butler J, et al (2015) Effect of vericiguat, a soluble guanylate-cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial. JAMA 314:2251–62 [CrossRef] [PubMed] [Google Scholar]
  • Buggey J, Mentz RJ, Pitt B, et al (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169:323–33 [CrossRef] [PubMed] [Google Scholar]
  • Felker GM, Lee KL, Bull DA, et al (2011) Diuretic strategies in patients with acute decompensated heart failure. New Engl J Med 364:797–805 [CrossRef] [PubMed] [Google Scholar]
  • Valente MA, Voors AA, Damman K, et al (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–93 [CrossRef] [PubMed] [Google Scholar]
  • Bart BA, Goldsmith SR, Lee KL, et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. New Engl J Med 367:2296–304 [CrossRef] [PubMed] [Google Scholar]
  • Lassus JP, Nieminen MS, Peuhkurinen K, et al (2010) Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 31:2791–8 [CrossRef] [PubMed] [Google Scholar]
  • Chen HH, Anstrom KJ, Givertz MM, et al (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310:2533–43 [CrossRef] [PubMed] [Google Scholar]
  • Konstam MA, Gheorghiade M, Burnett JC, Jr, et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319–31 [CrossRef] [PubMed] [Google Scholar]
  • Gheorghiade M, Konstam MA, Burnett JC, Jr, et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332–43 [CrossRef] [PubMed] [Google Scholar]
  • Massie BM, O'Connor CM, Metra M, et al (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363:1419–28 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.